Velos
announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management. Velos has partnered with Comaiba, Inc., a company focused on regulatory monitoring, risk management, and incident management. Velos and Comaiba will work together to help customers increase efficiency and decrease risk as they interpret, document, and execute to regulatory and clinical policies through their Velos-Comaiba Monitoring and Action solutions.
"We're impressed by Comaiba's solution and their deep domain expertise," said John McIlwain, CEO of Velos. "Now, active planning for and management of risk, and the continuous monitoring and auditing of policy-based compliance will be part of the solution. This increases efficiency even as it decreases organizational risk and exposure."
Healthcare institutions face financial, criminal, and reputational risks for non-compliance with regulatory mandates. These can include infringements of rules related to: patient safety and privacy, research compliance, billing and coding compliance, performance monitoring and quality compliance, among others. Healthcare institutions, pharmaceuticals and biotech companies have paid over $2 billion in fines for non-compliance in recent years, despite significant spending on compliance consulting services. Some infringements have resulted in criminal prosecutions.
Velos analysts and services teams have observed how healthcare organizations are dealing with these challenges in the current operational model—the process is reactive, manual, costly, and fragmented across departments. There is a clear need for proactive and holistic compliance management. The Comaiba solution provides enterprise-wide risk and compliance monitoring. The continuous monitoring is based on customer-adapted libraries of government and customer policies that automatically interpret regulatory guidelines in the customer's operational context.
The solution provides real-time monitoring and actionable intelligence for clinical teams, research teams, compliance officers, and executive management. This allows Velos customers to become proactive in their approach to improving quality, meeting compliance standards, and improving governance.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.